DELRAY BEACH, Fla., July 15, 2005 (PRIMEZONE) -- Hard To Treat Diseases, Incorporated (HTTD) (Pink Sheets:HTDS) announces today that the Company is preparing the appropriate legal response to the Federal Court's opinion.
It is now the Company's policy to post the legal response to the Court's Memorandum Opinion on our website as soon as it is filed with the Court. Shareholders and investors will be notified by press release.
Complete copies of the Court's Memorandum Opinion and Court Transcripts can be viewed on the Company's website at: www.htdsotc.com Click on Corporate, then click on Legal.
Management's intention and goal with this litigation has been to resolve the current dispute in the most efficient and economical manner to provide the maximum benefit to the Company and to HTTD's shareholders.
HTTD's CEO, Colm J. King, states, "The battle is not over! HTTD has assets and will continue as a Company defending its shareholder's rights. The Company's business strategy and plans will be released after the Court's ruling regarding HTTD's legal response. HTTD fully intends to become a respected biotech with the intense focus of negotiating a deal with a major biotech/drug company and attaining the goals of benefiting patients and HTTD's shareholders, the real owners of the Company."
Cautionary Note Regarding Forward-Looking Statements
The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Certain information included in this news release may contain or constitute forward-looking statements. These forward-looking statements are based on current expectations and are subject to risk and uncertainties. In connection with the "safe harbor" provisions of the Private Securities Litigation Act of 1995, Hard to Treat Diseases, Inc. provides the following cautionary statement identifying important factors which, among others, could cause the actual results or events to differ materially from those set forth or implied by the forward-looking statements and related assumptions.